Hospital Acquired Pneumonia Drugs Market, Global Outlook and Forecast 2023-2029

Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48ﾖ72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus.
This report aims to provide a comprehensive presentation of the global market for Hospital Acquired Pneumonia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital Acquired Pneumonia Drugs. This report contains market size and forecasts of Hospital Acquired Pneumonia Drugs in global, including the following market information:
Global Hospital Acquired Pneumonia Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Hospital Acquired Pneumonia Drugs Market Sales, 2018-2023, 2024-2029, (Kg)
Global top five Hospital Acquired Pneumonia Drugs companies in 2022 (%)
The global Hospital Acquired Pneumonia Drugs market was valued at US$ 2888.7 million in 2022 and is projected to reach US$ 3191.8 million by 2029, at a CAGR of 1.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Phase II Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hospital Acquired Pneumonia Drugs include Basilea Pharmaceutica, Meiji Holdings, Cubist Pharmaceutical, Aridis Pharmaceutical, Valneva, Bayer, GlaxoSmithKline, Merck and Achaogen, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hospital Acquired Pneumonia Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hospital Acquired Pneumonia Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (Kg)
Global Hospital Acquired Pneumonia Drugs Market Segment Percentages, by Type, 2022 (%)
    Phase II
    Early Phase (Phase I & II)
Global Hospital Acquired Pneumonia Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (Kg)
Global Hospital Acquired Pneumonia Drugs Market Segment Percentages, by Application, 2022 (%)
    Hospital Pharmacies
    Retail Pharmacies
    Drug Store
    E-Commerce
Global Hospital Acquired Pneumonia Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (Kg)
Global Hospital Acquired Pneumonia Drugs Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hospital Acquired Pneumonia Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Hospital Acquired Pneumonia Drugs revenues share in global market, 2022 (%)
Key companies Hospital Acquired Pneumonia Drugs sales in global market, 2018-2023 (Estimated), (Kg)
Key companies Hospital Acquired Pneumonia Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Basilea Pharmaceutica
    Meiji Holdings
    Cubist Pharmaceutical
    Aridis Pharmaceutical
    Valneva
    Bayer
    GlaxoSmithKline
    Merck
    Achaogen
    AstraZeneca
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hospital Acquired Pneumonia Drugs, market overview.
Chapter 2: Global Hospital Acquired Pneumonia Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Hospital Acquired Pneumonia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hospital Acquired Pneumonia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Hospital Acquired Pneumonia Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.